Decibel Expands General Admission Brand's International Footprint
Decibel Cannabis Company (TSXV: DB) (OTCQB: DBCCF) has signed a supply agreement and trademark license agreement with Keren Tirk to distribute General Admission branded medical cannabis flower in Israel. The initial shipment is expected in Q2 2025, targeting the mainstream segment of the Israeli medical cannabis market.
This expansion marks a significant milestone for Decibel, leveraging its domestic success to establish General Admission as a globally recognized brand. The company, which historically focused on premium price points, sees this as an opportunity to address larger volume opportunities in mainstream product segments. Following its Q4 2024 acquisition of AgMedica Biosciences, Decibel now operates with an EU-GMP certified facility, three cultivation facilities, and a processing and manufacturing center.
Decibel Cannabis Company (TSXV: DB) (OTCQB: DBCCF) ha firmato un accordo di fornitura e un accordo di licenza del marchio con Keren Tirk per distribuire fiori di cannabis medica a marchio General Admission in Israele. La prima spedizione è prevista per il secondo trimestre del 2025, mirando al segmento mainstream del mercato della cannabis medica israeliano.
Questa espansione segna un traguardo significativo per Decibel, che sfrutta il suo successo domestico per stabilire General Admission come un marchio riconosciuto a livello globale. L'azienda, che storicamente si è concentrata su fasce di prezzo premium, vede questa come un'opportunità per affrontare opportunità di volume più ampie nei segmenti di prodotto mainstream. Dopo l'acquisizione di AgMedica Biosciences nel quarto trimestre del 2024, Decibel ora opera con una struttura certificata EU-GMP, tre strutture di coltivazione e un centro di lavorazione e produzione.
Decibel Cannabis Company (TSXV: DB) (OTCQB: DBCCF) ha firmado un acuerdo de suministro y un acuerdo de licencia de marca con Keren Tirk para distribuir flores de cannabis medicinal de la marca General Admission en Israel. Se espera que el primer envío llegue en el segundo trimestre de 2025, dirigiéndose al segmento general del mercado de cannabis medicinal israelí.
Esta expansión marca un hito significativo para Decibel, aprovechando su éxito nacional para establecer a General Admission como una marca reconocida a nivel mundial. La compañía, que históricamente se ha centrado en precios premium, ve esto como una oportunidad para abordar oportunidades de mayor volumen en segmentos de productos generales. Tras su adquisición de AgMedica Biosciences en el cuarto trimestre de 2024, Decibel ahora opera con una instalación certificada por EU-GMP, tres instalaciones de cultivo y un centro de procesamiento y fabricación.
Decibel Cannabis Company (TSXV: DB) (OTCQB: DBCCF)는 Keren Tirk와 공급 계약 및 상표 라이선스 계약을 체결하고 이스라엘에서 General Admission 브랜드의 의료용 대마꽃을 유통합니다. 초기 배송은 2025년 2분기에 예상되며, 이스라엘 의료용 대마 시장의 주류 세그먼트를 목표로 하고 있습니다.
이번 확장은 Decibel의 중요한 이정표로, 자국 내 성공을 활용하여 General Admission을 세계적으로 인정받는 브랜드로 자리매김하고자 합니다. 과거 프리미엄 가격대에 집중해온 이 회사는 일반 제품 세그먼트에서 더 큰 물량 기회를 잡을 수 있는 기회로 보고 있습니다. 2024년 4분기에 AgMedica Biosciences를 인수한 후, Decibel은 현재 EU-GMP 인증 시설, 세 개의 재배 시설 및 가공 및 제조 센터를 운영하고 있습니다.
Decibel Cannabis Company (TSXV: DB) (OTCQB: DBCCF) a signé un accord de fourniture et un accord de licence de marque avec Keren Tirk pour distribuer des fleurs de cannabis médical de marque General Admission en Israël. La première expédition est prévue pour le deuxième trimestre 2025, visant le segment grand public du marché israélien du cannabis médical.
Cette expansion marque une étape importante pour Decibel, qui utilise son succès national pour établir General Admission comme une marque reconnue à l'échelle mondiale. L'entreprise, qui s'est historiquement concentrée sur des prix premium, voit cela comme une opportunité de répondre à des besoins de volume plus importants dans les segments de produits grand public. Suite à l'acquisition d'AgMedica Biosciences au quatrième trimestre 2024, Decibel opère désormais avec une installation certifiée EU-GMP, trois installations de culture et un centre de transformation et de fabrication.
Decibel Cannabis Company (TSXV: DB) (OTCQB: DBCCF) hat einen Liefervertrag und einen Lizenzvertrag für die Marke mit Keren Tirk unterzeichnet, um General Admission markenrechtlich geschützte medizinische Cannabisblüten in Israel zu vertreiben. Die erste Lieferung wird für das zweite Quartal 2025 erwartet und zielt auf das Mainstream-Segment des israelischen medizinischen Cannabismarktes ab.
Diese Expansion stellt einen bedeutenden Meilenstein für Decibel dar, da das Unternehmen seinen nationalen Erfolg nutzt, um General Admission als weltweit anerkanntes Markenzeichen zu etablieren. Das Unternehmen, das historisch auf Premium-Preissegmenten fokussiert war, sieht dies als Gelegenheit, um größere Volumenmöglichkeiten in Mainstream-Produktsegmenten zu erschließen. Nach der Übernahme von AgMedica Biosciences im vierten Quartal 2024 betreibt Decibel nun eine nach EU-GMP zertifizierte Einrichtung, drei Anbauanlagen und ein Verarbeitungs- und Produktionszentrum.
- Expansion into international market (Israel) through medical cannabis supply agreement
- Strategic entry into mainstream segment, expanding beyond premium-only focus
- Enhanced production capabilities with EU-GMP certified facility following AgMedica acquisition
- Complementary product positioning to existing Qwest branded products
- None.
"General Admission has solidified itself as one of the top cannabis brands in
Key Highlights
- Decibel to supply General Admission branded, Medical Cannabis for distribution to Israel Medical Cannabis patients
- Initial shipment of General Admission branded products expected Q2 2025
- General Admission flower products will be positioned in the mainstream segment
- Launch of General Admission is complimentary to Qwest branded products and provides incremental volume opportunity for Decibel
- Historically Decibel targeted only premium price point product segments Internationally, launching General Admission is the starting point to address the larger volume opportunities in the mainstream product segments
About Decibel
Decibel is a consumer-focused cannabis company focused on delivering products that delight customers through a commitment to robust innovation and product quality. With brands like General Admission, Qwest, and Vox, Decibel's offerings are available across
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
Cautionary Statements
Forward-Looking Statements
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements.
In this news release, forward-looking statements relate to, among other things, receipt of all regulatory approvals in connection therewith, General Admission being positively received by the Israeli medical cannabis market, Decibel's anticipated commitments from its counterparty, that the General Admission brand will continue to have domestic success which may be translated into international success, the international regulations for brand licensing, the demand for Canadian cannabis products and cannabis brands; and Decibel's ability to delight customers through a commitment to robust innovation and product quality. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, the Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.
Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: the Company's ability to complete the deliveries and obligations described herein or at all or to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; and the delay or failure to receive regulatory or other approvals. Many of these risks and uncertainties and additional risk factors generally applicable to the Company are described in the Company's management's discussion and analysis for the three and six months ended June 30, 2024 and 2023, which are available under the Company's profile at www.sedarplus.ca.
Readers are cautioned that the foregoing list of assumptions and risk factors is not exhaustive. The forward-looking statements contained herein are expressly qualified in their entirety by this cautionary statement. The forward-looking statements included in this news release are made as of the date hereof and Decibel does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, developments or otherwise unless so required by applicable securities laws.
View original content to download multimedia:https://www.prnewswire.com/news-releases/decibel-expands-general-admission-brands-international-footprint-302378293.html
SOURCE Decibel Cannabis Company Inc.
FAQ
When will Decibel (DBCCF) begin shipping General Admission products to Israel?
What market segment will General Admission target in Israel's medical cannabis market?
How many facilities does Decibel (DBCCF) operate after the AgMedica acquisition?
Who is Decibel's distribution partner for General Admission products in Israel?
